Will manufacture biologic medicines for Roche at the Incheon, South Korea plants
South Korean contract manufacturer Samsung BioLogics has signed a manufacturing agreement with F. Hoffmann-La Roche under which Samsung will manufacture Roche's proprietary commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea, of which one is currently under construction.
Terms of the agreement have not been disclosed, including financial terms and products to be manufactured.
'We are pleased to announce this strategic manufacturing relationship with Roche and look forward to delivering best-in-class manufacturing services with the highest global quality standards,' said Tae-Han Kim, President and CEO of Samsung BioLogics.
'This collaboration with the world's largest biotech company is an important milestone for Samsung as it validates our long term strategy of becoming a leader in biopharmaceutical manufacturing.'